文献速递肝胆胰外科围术期管理与 ERAS

机器人胰十二指肠切除术可能优于开腹手术的肿瘤学结局:倾向匹配单中心研究

Robotic pancreaticoduodenectomy may offer improved oncologic outcomes over open surgery: a propensity-matched single-institution study.
PubMed 文献 · Surg Endosc · 2020-04-23

该单中心回顾性研究将2008—2019年因胰腺腺癌行机器人胰十二指肠切除术(RPD)的38例与倾向匹配的38例开腹胰十二指肠切除术(OPD)比较。RPD淋巴结检出数更高(21.5 vs 13.5;p=0.0036)、延迟性胃排空(DGE)更低(3% vs 32%;p=0.0009)、住院时间更短(7.5 vs 9;p=0.0209),R0切除率与淋巴结阳性率无差异,中位总生存有改善趋势但未达统计学显著(30.4 vs 23.0个月;p=0.1105)。

要点

  • RPD淋巴结检出数显著高于OPD(21.5 vs 13.5;p=0.0036)。
  • RPD的DGE发生率显著更低(3% vs 32%;p=0.0009),住院时间更短(7.5 vs 9;p=0.0209)。
  • 中位总生存改善趋势未达统计学显著(30.4 vs 23.0个月;p=0.1105)。

核心结论

  • RPD在短期术后获益方面不劣于甚至优于OPD,并可能带来更好的肿瘤学结局。
  • RPD淋巴结检出数显著更高、DGE显著更低,作者认为这可能与炎症反应降低有关并可能改善总生存。

研究设计与样本

  • 单中心三级医院2008—2019年因胰腺腺癌行RPD的回顾性研究。
  • 38例RPD按人口学与肿瘤学特征与38例OPD倾向匹配,采用Mann-Whitney U检验、log rank检验与Kaplan-Meier法比较结局。

主要发现

  • RPD淋巴结检出数显著高于OPD(21.5 vs 13.5;p=0.0036),手术时间与估计出血量(EBL)无差异。
  • RPD的DGE显著更低(3% vs 32%;p=0.0009),住院时间显著更短(7.5 vs 9;p=0.0209)。
  • 漏、感染、出血、尿潴留、肠梗阻及30/90天再入院、90天死亡率均无差异。
  • R0切除率与淋巴结阳性比例相当;中位总生存有改善趋势(30.4 vs 23.0个月;p=0.1105),复发时间更长(402 vs 284天;p=0.7471)。
  • OPD局部复发率为RPD的两倍(16% vs 8%),远处复发无差异。

临床怎么用

  • 在筛选合适的胰腺腺癌患者中,RPD可作为可获得更高淋巴结检出数和更低DGE的术式选择。
  • RPD的肿瘤学长期获益尚需进一步研究证实,决策时应结合中心经验与患者情况。

局限性

  • 单中心回顾性设计,样本量小(各38例),倾向匹配后仍可能存在残余混杂。
  • 总生存与复发时间差异未达统计学显著,肿瘤学获益证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The robotic platform in pancreatic disease has gained popularity in the hepatobiliary community due to significant advantages it technically offers over conventional open and laparoscopic techniques. Despite promising initial studies, there remains scant literature on operative and oncologic outcomes of robotic pancreaticoduodenectomy (RPD) for pancreatic adenocarcinoma. METHODS: A retrospective review evaluated all RPD performed for pancreatic adenocarcinoma from 2008 to 2019 in a single tertiary institution. RPD cases were matched to open cases (OPD) by demographic and oncologic characteristics and outcomes compared using Mann-Whitney U test, log rank tests, and Kaplan-Meier methods. RESULTS: Thirty-eight RPD cases were matched to 38 OPD. RPD had significantly higher lymph node (LN) yield (21.5 vs 13.5; p = 0.0036) and no difference in operative time or estimated blood loss (EBL). RPD had significantly lower rate of delayed gastric emptying (DGE) (3% vs 32%; p = 0.0009) but no difference in leaks, infections, hemorrhage, urinary retention ,or ileus. RPD had significantly shorter length of stay (LOS) (7.5 vs. 9; p = 0.0209). There were no differences in 30- or 90-day readmissions or 90-day mortality. There was an equivalent R0 resection rate and LN positivity ratio. There was a trend towards improved median overall survival in RPD (30.4 vs. 23.0 months; p = 0.1105) and longer time to recurrence (402 vs. 284 days; p = 0.7471). OPD had two times the local recurrent rate (16% vs. 8%) but no difference in distant recurrence. CONCLUSIONS: While the feasibility and safety of RPD has been demonstrated, the impact on oncologic outcomes had yet to be investigated. We demonstrate that RPD not only offers similar if not superior immediate post-operative benefit by decreasing DGE but more importantly may offer improved oncologic outcomes. The significantly higher LN yield and decreased inflammatory response demonstrated in robotic surgery may improve overall survival.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Baimas-George M, Watson M, Murphy KJ, et al. Robotic pancreaticoduodenectomy may offer improved oncologic outcomes over open surgery: a propensity-matched single-institution study. Surg Endosc. 2020. PMID: 32328825. doi:10.1007/s00464-020-07564-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。